Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43rd Annual Global Healthcare Conference, on June 15, 2022, at 10:40 a.m. PT.
Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website athttps://investors.ginkgobioworks.com/events.
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visitwww.ginkgobioworks.com.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
| Last Trade: | US$8.12 |
| Daily Change: | -0.19 -2.29 |
| Daily Volume: | 1,128,337 |
| Market Cap: | US$367.020M |
April 22, 2025 April 10, 2025 February 21, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
